Nektar Therapeutics Shares Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis
Nektar Therapeutics, a developer of innovative immunotherapy treatments, recently published significant findings from its REZOLVE-AD trial in the renowned medical journal, The Lancet. This Phase 2b study evaluated the efficacy and safety of rezpegaldesleukin, a biologic targeting moderate-to-severe atopic dermatitis (AD). In this double-blind, placebo-controlled study, data demonstrated that rezpegaldesleukin not only met all primary endpoints but also showcased substantial improvements across secondary metrics within a 16-week induction period.
Rezpegaldesleukin is a pioneering regulatory T-cell (T-reg) stimulator that seeks to restore immune balance in patients suffering from autoimmune disorders. By targeting the interleukin-2 (IL-2) receptor complex, it promotes the proliferation of T-reg cells crucial for regulating the immune response. The results of this study are particularly encouraging, providing robust evidence of clinical benefits that may redefine treatment paradigms for atopic dermatitis.
Dr. Jonathan I. Silverberg, the lead investigator and professor of dermatology at George Washington University, stated, "These results illustrate the promising potential of selectively expanding regulatory T cells for achieving meaningful clinical benefits in atopic dermatitis patients. The rapid onset of efficacy and a favorable safety profile highlight the unique advantages of rezpegaldesleukin."
Carried out across 107 sites in ten countries, the study involved 393 adult participants who were randomized into various groups, receiving different dosing regimens of rezpegaldesleukin or placebo. Participants receiving the 24 µg/kg dosage every two weeks experienced a notable 61% improvement in the Eczema Area and Severity Index (EASI) by Week 16, exceeding the 31% improvement seen in the placebo group (p<0.0001). Moreover, the study consistently demonstrated dose-dependent responses, indicating a promising path for maintenance therapies as well.
Key secondary endpoints measuring itch relief and overall skin condition showed significant enhancements for those treated with rezpegaldesleukin compared to placebo. For example, EASI-75 responses were noted in 42% of patients receiving the active treatment versus just 17% in the placebo group. Furthermore, significant itch relief for those with severe discomfort was also observed—54% of participants achieved a meaningful reduction in their itch scores compared to 24% in the placebo cohort.
Among safety reports, rezpegaldesleukin maintained a favorable profile, with serious adverse events occurring in just 2% of participants and no incidents of increased risk for infections, distinguishing it from existing treatments that focus mainly on suppressing inflammation.
The findings from the REZOLVE-AD trial reinforce the significance of regulatory T-cell modulation as a revolutionary strategy in handling chronic inflammatory diseases. Nektar Therapeutics plans to advance the development of rezpegaldesleukin in its Phase 3 ZENITH AD program.
Dr. Jonathan Zalevsky, Chief Research and Development Officer at Nektar, remarked on the significance of this research, referencing the 2025 Nobel Prize acknowledgment of T-reg cell discovery. He expressed optimism about rezpegaldesleukin’s potential, stating, "This study paves the way for continued exploration of T-reg modulation as a therapeutic avenue in the treatment of atopic dermatitis and could potentially change our approach to managing other autoimmune conditions."
With future Phase 3 trials underway, including global studies intended to recruit patients previously untreated with biologics, rezpegaldesleukin stands to introduce a fresh perspective on addressing the significant unmet needs for those suffering from atopic dermatitis. As the medical community readies for further developments, the hope is that such innovative therapies will provide long-awaited relief for patients contending with chronic skin afflictions.
Nektar Therapeutics continues its mission to lead in the field of immunotherapy targeting autoimmune diseases. As they proceed with ongoing clinical trials, their commitment to improvement and advancement in patient care remains unwavering, marking a progressive step forward for dermatological treatments.
Rezpegaldesleukin is a pioneering regulatory T-cell (T-reg) stimulator that seeks to restore immune balance in patients suffering from autoimmune disorders. By targeting the interleukin-2 (IL-2) receptor complex, it promotes the proliferation of T-reg cells crucial for regulating the immune response. The results of this study are particularly encouraging, providing robust evidence of clinical benefits that may redefine treatment paradigms for atopic dermatitis.
Dr. Jonathan I. Silverberg, the lead investigator and professor of dermatology at George Washington University, stated, "These results illustrate the promising potential of selectively expanding regulatory T cells for achieving meaningful clinical benefits in atopic dermatitis patients. The rapid onset of efficacy and a favorable safety profile highlight the unique advantages of rezpegaldesleukin."
Carried out across 107 sites in ten countries, the study involved 393 adult participants who were randomized into various groups, receiving different dosing regimens of rezpegaldesleukin or placebo. Participants receiving the 24 µg/kg dosage every two weeks experienced a notable 61% improvement in the Eczema Area and Severity Index (EASI) by Week 16, exceeding the 31% improvement seen in the placebo group (p<0.0001). Moreover, the study consistently demonstrated dose-dependent responses, indicating a promising path for maintenance therapies as well.
Key secondary endpoints measuring itch relief and overall skin condition showed significant enhancements for those treated with rezpegaldesleukin compared to placebo. For example, EASI-75 responses were noted in 42% of patients receiving the active treatment versus just 17% in the placebo group. Furthermore, significant itch relief for those with severe discomfort was also observed—54% of participants achieved a meaningful reduction in their itch scores compared to 24% in the placebo cohort.
Among safety reports, rezpegaldesleukin maintained a favorable profile, with serious adverse events occurring in just 2% of participants and no incidents of increased risk for infections, distinguishing it from existing treatments that focus mainly on suppressing inflammation.
The findings from the REZOLVE-AD trial reinforce the significance of regulatory T-cell modulation as a revolutionary strategy in handling chronic inflammatory diseases. Nektar Therapeutics plans to advance the development of rezpegaldesleukin in its Phase 3 ZENITH AD program.
Dr. Jonathan Zalevsky, Chief Research and Development Officer at Nektar, remarked on the significance of this research, referencing the 2025 Nobel Prize acknowledgment of T-reg cell discovery. He expressed optimism about rezpegaldesleukin’s potential, stating, "This study paves the way for continued exploration of T-reg modulation as a therapeutic avenue in the treatment of atopic dermatitis and could potentially change our approach to managing other autoimmune conditions."
With future Phase 3 trials underway, including global studies intended to recruit patients previously untreated with biologics, rezpegaldesleukin stands to introduce a fresh perspective on addressing the significant unmet needs for those suffering from atopic dermatitis. As the medical community readies for further developments, the hope is that such innovative therapies will provide long-awaited relief for patients contending with chronic skin afflictions.
Nektar Therapeutics continues its mission to lead in the field of immunotherapy targeting autoimmune diseases. As they proceed with ongoing clinical trials, their commitment to improvement and advancement in patient care remains unwavering, marking a progressive step forward for dermatological treatments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.